GRAIL, Inc. Common Stock (GRAL) is a publicly traded Healthcare sector company. As of May 21, 2026, GRAL trades at $65.50 with a market cap of $2.61B and a P/E ratio of -6.29. GRAL moved +8.81% today. Year to date, GRAL is -31.04%; over the trailing twelve months it is +67.93%. Its 52-week range spans $12.33 to $118.84. Analyst consensus is buy with an average price target of $67.04. Rallies surfaces GRAL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GRAIL to Unveil 174,000-Patient Galleri Trial Data at 2026 ASCO Meeting: GRAIL will unveil expanded NHS-Galleri results from 142,000 participants and full PATHFINDER 2 data from 32,000 evaluable subjects at the May 29–June 2, 2026 ASCO Annual Meeting in Chicago. Combined enrollment of over 174,000 participants underscores Galleri’s clinical rigor and potential to shift cancer detection earlier.
| Metric | Value |
|---|---|
| Price | $65.50 |
| Market Cap | $2.61B |
| P/E Ratio | -6.29 |
| EPS | $-10.30 |
| Dividend Yield | 0.00% |
| 52-Week High | $118.84 |
| 52-Week Low | $12.33 |
| Volume | 51 |
| Avg Volume | 0 |
| Revenue (TTM) | $156.12M |
| Net Income | $-395.32M |
| Gross Margin | 0.00% |
7 analysts cover GRAL: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $67.04.